特发性多中心型Castleman病TAFRO亚型1例并文献复习
Idiopathic multicentric Castleman disease TAFRO subtype: report of 1 case and review of literature
摘要
目的:提高对特发性多中心型Castleman病TAFRO亚型(iMCD-TAFRO)的认识。方法:回顾性分析上海中医药大学附属普陀医院2025年5月收治的1例iMCD-TAFRO患者的临床资料,并进行相关文献复习。结果:患者为71岁男性,因颜面部水肿、乏力就诊,综合淋巴结组织病理、临床表现及相关辅助检查结果,诊断为iMCD-TAFRO。一线予司妥昔单抗+甲泼尼龙联合沙利度胺+环磷酰胺方案治疗。3周后患者部分缓解,6周后达症状和生化指标的完全缓解。结论:iMCD-TAFRO是Castleman病的侵袭性亚型,常表现为严重的细胞因子风暴综合征,以血小板减少、全身水肿、肾功能损害、器官增大尤其淋巴结肿大为主要临床特征。高频率司妥昔单抗+大剂量甲泼尼龙冲击治疗可快速有效控制病情。
Objective:To improve the recognition of idiopathic multicentric Castleman disease TAFRO subtype (iMCD-TAFRO).Methods:The clinical data of a patient with iMCD-TAFRO who was admitted to Putuo Hospital of Shanghai University of Traditional Chinese Medicine in May 2025 were retrospectively analyzed, along with a review of the relevant literature.Results:The patient was a 71-year-old male diagnosed with iMCD-TAFRO based on lymph node histopathology, clinical presentation and ancillary laboratory findings. He was treated with a first-line regimen comprising siltuximab and methylprednisolone, combined with thalidomide and cyclophosphamide. After 3 weeks, he achieved partial remission, and after 6 weeks, he achieved complete remission of both symptoms and biochemical markers.Conclusions:iMCD-TAFRO is an aggressive subtype of Castleman disease. Patients often present with severe cytokine storm syndrome, characterized by thrombocytopenia, anasarca, renal dysfunction and organomegaly, particularly lymphadenopathy. High-frequency siltuximab combined with high-dose methylprednisolone can rapidly and effectively control the disease.
年,卷(期):
2026, 35(7)
在线出版日期:
2026年7月25日